



Verastem to Present at Upcoming Conferences

November 26, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming scientific and investor conferences. The presentation details are as follows:

- 6th Annual 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 1:40 p.m. ET at The Four Seasons Hotel in Boston, MA
- Oppenheimer & Co. 24th Annual Healthcare Conference on Wednesday, December 11, 2013 at 3:55 p.m. ET at The Crowne Plaza Hotel in New York City, NY
- 2013 San Antonio Breast Cancer Symposium on Tuesday, December 10 through Saturday, December 14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, TX

Title: Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target breast cancer stem cells

Presentation #: P2-09-14

Date and Time: Thursday, Dec. 12, 2013 7:00 – 9:00 a.m. CT

Session: Poster Session 2

Location: Exhibit Halls A-B

Webcasts of the Deutsche Bank and Oppenheimer & Co. presentations can be accessed by visiting the investors section of the Company's website at www.verastem.com. Replays of each of the webcasts will be archived on the Verastem website for 30 days following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of [cancer stem cells](#). Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.

Brian Sullivan, 617-252-9314

bsullivan@verastem.com